blackdovfx/iStock via Getty Images Introduction Quantinuum ( QNT ) is preparing to go public on June 4, offering 21,052,632 shares on the NASDAQ at an indicated price range of $45-50 per share, with an overallotment option of 3,157,894 shares given to the lead underwriters, J.P. Morgan and Morgan Stanley. If fully exercised, this would result in an Enterprise Value of $12.7 billion at the midpoint...
blackdovfx/iStock via Getty Images Introduction Quantinuum ( QNT ) is preparing to go public on June 4, offering 21,052,632 shares on the NASDAQ at an indicated price range of $45-50 per share, with an overallotment option of 3,157,894 shares given to the lead underwriters, J.P. Morgan and Morgan Stanley. If fully exercised, this would result in an Enterprise Value of $12.7 billion at the midpoint, a slight increase from the $10 billion valuation the company was awarded from a Series B raise in November 2025. The company, which was formed in 2021 through the combination of Honeywell Quantum Solutions and Cambridge Quantum, is a full-stack developer of quantum hardware and software products for integration in hybrid systems incorporating classical computing (CPUs), edge computing (GPUs), and quantum computing (QCUs). Quantinuum notes in its S-1/A of May 26, 2026 that their QCCD architecture, first introduced in the early 2000s, has the highest accuracy rates (99.921% average two-qubit gate fidelity) in the industry. Their current quantum system, Helios, is capable of delivering 48 logical qubits, while new releases are intended to reach 100 logical qubits (Sol, planned launch in 2027) and hundreds of qubits (Apollo, planned launch in 2029). Honeywell, which has served as a testing ground and supply chain partner, has indicated it plans to remain a customer and partner of the company following the IPO. Quantinuum, which currently markets its products to companies in the pharmaceuticals, materials science, financial services, government and industrial sectors, boasts established relationships with prominent customers, such as JPMorganChase, Amgen, and Mitsui & Co., and has raised capital from leading companies including NVentures (NVidia's venture arm), Amgen, and Serendipity Capital. The company references two overriding goals in the S-1: Grow and maintain market leadership in on-premises and cloud-based quantum solutions, reinforcing scale advantages and customer sti...